Neuroblastoma Trial

We are developing CMD-501 for the treatment of neuroblastoma. CMD-501 is an autologous cell therapy which utilizes our natural killer T (NKT) cell platform technology in combination with genetically engineered chimeric antigen receptors (CARs) and secretion of the IL-15 cytokine to sustain the activity of the therapeutic cells within the immunosuppressive tumor microenvironment.

See our press release regarding the first dosed patient here.

More information about the Neuroblastoma Trial can be found here https://www.bcm.edu/research/clinical-trials/h-41033